CA2556436C - Process for preparing anti-a.beta. antibody - Google Patents

Process for preparing anti-a.beta. antibody Download PDF

Info

Publication number
CA2556436C
CA2556436C CA2556436A CA2556436A CA2556436C CA 2556436 C CA2556436 C CA 2556436C CA 2556436 A CA2556436 A CA 2556436A CA 2556436 A CA2556436 A CA 2556436A CA 2556436 C CA2556436 C CA 2556436C
Authority
CA
Canada
Prior art keywords
antibody
peptide
cells
gel
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2556436A
Other languages
English (en)
French (fr)
Other versions
CA2556436A1 (en
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B. Mcclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2556436A1 publication Critical patent/CA2556436A1/en
Application granted granted Critical
Publication of CA2556436C publication Critical patent/CA2556436C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CA2556436A 2004-02-23 2005-02-17 Process for preparing anti-a.beta. antibody Expired - Fee Related CA2556436C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
CA2556436A1 CA2556436A1 (en) 2005-09-09
CA2556436C true CA2556436C (en) 2014-04-01

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2556436A Expired - Fee Related CA2556436C (en) 2004-02-23 2005-02-17 Process for preparing anti-a.beta. antibody

Country Status (20)

Country Link
US (1) US20070190046A1 (enExample)
EP (1) EP1720909B1 (enExample)
JP (1) JP4851348B2 (enExample)
KR (2) KR100889430B1 (enExample)
CN (1) CN1922209B (enExample)
AT (1) ATE534667T1 (enExample)
AU (1) AU2005217596B2 (enExample)
BR (1) BRPI0507856A (enExample)
CA (1) CA2556436C (enExample)
CY (1) CY1112162T1 (enExample)
DK (1) DK1720909T3 (enExample)
EA (1) EA009872B1 (enExample)
ES (1) ES2375627T3 (enExample)
IL (1) IL177611A (enExample)
NO (1) NO20064239L (enExample)
PL (1) PL1720909T3 (enExample)
PT (1) PT1720909E (enExample)
SI (1) SI1720909T1 (enExample)
UA (1) UA93181C2 (enExample)
WO (1) WO2005082939A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
NZ568012A (en) 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
RU2498999C2 (ru) 2006-07-14 2013-11-20 Ац Иммуне Са Гуманизированное антитело к амилоиду бета
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PL2238166T3 (pl) 2007-10-05 2014-07-31 Genentech Inc Zastosowanie przeciwciała anty-Beta amyloidowego w chorobach oczu
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
EP2376120A2 (en) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
HRP20150831T1 (hr) 2008-12-19 2015-10-09 Biogen International Neuroscience Gmbh Humana anti-alfa- sinuklein auto-protutijela
BR112012009997A2 (pt) 2009-11-12 2019-09-24 Genentech Inc ''método para aumentar a densidade de espinhas dentriticas nos neurônios de um paciente com um distúrbios cognitivo ou psiquiatrico,método de manutenção da cognição em um sujeito durante o processo de envelhecimento,uso de um antagonista de dr6 na preparação de um medicamento para uso em um paciente com um disturbio cognitivo uo psiquíatrico e uso de um antagonista de p75 na preparação de um medicamento para uso em um paciente com um distúrbio cognitivo ou psiquiátrico''
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
PL2723379T3 (pl) 2011-06-23 2019-05-31 Biogen Int Neuroscience Gmbh Cząsteczki wiążące przeciwko alfa-synukleinie
EP2892506B1 (en) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Treating hearing loss with the gamma-secretase inhibitor ly411575
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
EA006606B1 (ru) * 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002258808A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
EA200601545A1 (ru) 2007-02-27
WO2005082939A3 (en) 2005-10-27
CA2556436A1 (en) 2005-09-09
ES2375627T3 (es) 2012-03-02
BRPI0507856A (pt) 2007-07-10
WO2005082939A2 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
IL177611A0 (en) 2006-12-10
AU2005217596A1 (en) 2005-09-09
KR100889430B1 (ko) 2009-03-23
EP1720909A2 (en) 2006-11-15
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
CY1112162T1 (el) 2015-12-09
KR20090005410A (ko) 2009-01-13
JP4851348B2 (ja) 2012-01-11
CN1922209B (zh) 2012-09-05
CN1922209A (zh) 2007-02-28
EP1720909B1 (en) 2011-11-23
SI1720909T1 (sl) 2012-01-31
KR20060126785A (ko) 2006-12-08
NO20064239L (no) 2006-11-20
ATE534667T1 (de) 2011-12-15
US20070190046A1 (en) 2007-08-16
IL177611A (en) 2013-05-30
PT1720909E (pt) 2011-12-23
JP2008500279A (ja) 2008-01-10
EA009872B1 (ru) 2008-04-28
UA93181C2 (ru) 2011-01-25

Similar Documents

Publication Publication Date Title
AU2005217596B2 (en) Anti-ABeta antibody
US20240190952A1 (en) IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases
US11078261B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
JP6462750B2 (ja) 二重特異性抗ｖｅｇｆ／抗ａｎｇ−２抗体及び眼血管疾患の処置におけるそれらの使用
US20230381308A1 (en) Neutralizing anti-tl1a monoclonal antibodies
KR101370253B1 (ko) 재조합 항체의 재접힘 방법
JP2003523764A (ja) Ａβペプチドを隔離するヒト化抗体
KR20090019911A (ko) 아밀로이드 β(1-42) 올리고머, 이의 유도체, 이에 대한 항체, 이의 제조 방법 및 용도
KR20080090408A (ko) 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
CN105085679B (zh) 全人源抗rankl抗体
CN115803347A (zh) 抗klk2抗体的抗独特型抗体
MXPA06009560A (en) Anti-abeta antibody
US20250353904A1 (en) Preventative Agent or Therapeutic Agent for Amyotrophic Lateral Sclerosis, Parkinson&#39;s Disease, Huntington&#39;s Disease, Spinocerebellar Ataxia, Aging-Related Degenerative or Neurological Disease, Brain Aging, or Diseases Associated With Brain Aging
US20240025985A1 (en) Agent for Preventing or Treating Frontotemporal Lobar Degeneration
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170217